Institute for Wealth Management LLC. Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Institute for Wealth Management LLC. acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 580,997 shares of the company’s stock, valued at approximately $3,928,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $26,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares during the last quarter. Finally, KBC Group NV increased its position in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after buying an additional 3,377 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $7.69 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The firm has a fifty day moving average price of $7.00 and a 200-day moving average price of $6.94. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the firm earned ($0.43) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the transaction, the director now owns 7,066,113 shares of the company’s stock, valued at approximately $53,985,103.32. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.